NCUEarnings•globenewswire•
NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update
Sentiment:Negative (30)
Summary
First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 20, 2025 by globenewswire